Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bleomycin pharmacokinetics in man. I. Intravenous administration.

Literature DB >> 86392

Bleomycin pharmacokinetics in man. I. Intravenous administration.

D S Alberts, H S Chen, R Liu, K J Himmelstein, M Mayersohn, D Perrier, J Gross, T Moon, A Broughton, S E Salmon.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Bleomycin

Year: 1978 PMID： 86392 DOI： 10.1007/BF00253118

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

× No keyword cloud information.

13 in total

1. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors: A J Sedman; J G Wagner
Journal: J Pharm Sci Date: 1976-07 Impact factor: 3.534

2. Statistical estimations in pharmacokinetics.

Authors: H G Boxenbaum; S Riegelman; R M Elashoff
Journal: J Pharmacokinet Biopharm Date: 1974-04

3. Letter: New components of bleomycin.

Authors: A Fujii; T Takita; K Maeda; H Umezawa
Journal: J Antibiot (Tokyo) Date: 1973-07 Impact factor: 2.649

4. Letter: Chemistry of bleomycin. XI. The structures of the terminal amines.

Authors: A Fujii; T Takita; K Maeda; H Umezawa
Journal: J Antibiot (Tokyo) Date: 1973-07 Impact factor: 2.649

5. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance.

Authors: T Onuma; J F Holland; H Masuda; J A Waligunda; G A Goldberg
Journal: Cancer Date: 1974-05 Impact factor: 6.860

6. A clinical review of bleomycin--a new antineoplastic agent.

Authors: R H Blum; S K Carter; K Agre
Journal: Cancer Date: 1973-04 Impact factor: 6.860

7. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.

Authors: S T Crooke; R L Comis; L H Einhorn; J E Strong; A Broughton; A W Prestayko
Journal: Cancer Treat Rep Date: 1977-12

8. New antibiotics, bleomycin A and B.

Authors: H Umezawa; K Maeda; T Takeuchi; Y Okami
Journal: J Antibiot (Tokyo) Date: 1966-09 Impact factor: 2.649

9. Intracavitary bleomycin in the management of malignant effusions.

Authors: W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal: Cancer Date: 1976-11 Impact factor: 6.860

10. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function.

Authors: S T Crooke; F Luft; A Broughton; J Strong; K Casson; L Einhorn
Journal: Cancer Date: 1977-04 Impact factor: 6.860

18 in total

10. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay.

Authors: K Inoue; T Mukaiyama; I Mitsui; M Ogawa
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

Bleomycin pharmacokinetics in man. I. Intravenous administration.

1. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

2. Statistical estimations in pharmacokinetics.

3. Letter: New components of bleomycin.

4. Letter: Chemistry of bleomycin. XI. The structures of the terminal amines.

5. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance.

6. A clinical review of bleomycin--a new antineoplastic agent.

7. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.

8. New antibiotics, bleomycin A and B.

9. Intracavitary bleomycin in the management of malignant effusions.

10. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function.

Review 1. Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge.

2. Bleomycin pharmacokinetics in man. II. Intracavitary administration.

3. Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Review 4. Pharmacokinetic drug interactions of commonly used anticancer drugs.

5. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

6. Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin.

Review 7. Clinical management of cytotoxic drug overdose.

8. Phase I trial of tallysomycin S10b, a bleomycin analogue.

Review 9. Mechanisms of bleomycin-induced lung damage.

10. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay.